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Traumatic brain injury (TBI) represents a major public health problem, which is associated
with neurological dysfunction. In severe or moderate cases of TBI, in addition to its
high mortality rate, subjects may encounter diverse behavioral dysfunctions. Previous
reports suggest that an association between TBI and chronic pain syndromes tends to
be more common in patients with mild forms of brain injury. Despite causing minimal
brain damage, mild TBI (mTBI) often leads to persistent psychologically debilitating
symptoms, which can include anxiety, various forms of memory and learning deficits,
and depression. At present, no effective treatment options are available for these
symptoms, and little is known about the complex cellular activity affecting neuronal
activity that occurs in response to TBI during its late phase. Here, we used a
mouse model to investigate the effect of Palmitoylethanolamide (PEA) on both the
sensorial and neuropsychiatric dysfunctions associated with mTBI through behavioral,
electrophysiological, and biomolecular approaches. Fourteen-day mTBI mice developed
anxious, aggressive, and reckless behavior, whilst depressive-like behavior and impaired
social interactions were observed from the 60th day onward. Altered behavior was
associated with changes in interleukin 1 beta (IL-1β) expression levels and neuronal
firing activity in the medial prefrontal cortex. Compared with vehicle, PEA restored the
behavioral phenotype and partially normalized the biochemical and functional changes
occurring at the supraspinal level. In conclusion, our findings reveal some of the
supraspinal modifications responsible for the behavioral alterations associated with
mTBI and suggest PEA as a pharmacological tool to ameliorate neurological dysfunction
induced by the trauma.
Keywords: traumatic brain injury, Palmitoylethanolamide, medial prefrontal cortex, mice depression, aggressive
behavior, in vivo electrophysiology
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INTRODUCTION
Traumatic brain injury (TBI) represents a major public health
problem, which is associated with neurological dysfunction. It
may pertain to injuries with severities ranging from moderate
to high (Saatman et al., 2008), and may be accompanied by
several neurological dysfunctions, inflammatory processes, and
cell death (Arciniegas, 2011). TBI is divided into two phases:
primary injury and the consequent secondary reaction. It is
believed that primary cell death due to the injury cannot really
be prevented, whereas the secondary neuropsychiatric changes
could potentially be managed by therapeutic intervention
because they are driven by several pathogenic parameters
(Arciniegas et al., 2005). In the past, it has been demonstrated,
in an animal model of mild TBI (mTBI), that the induction
of oxidative and nitrosative damage leads to cerebrovascular
inflammation (Abdul-Muneer et al., 2013). In fact, several
animal models of TBI have been developed (Shultz et al., 2016).
Moreover, neuroinflammatory and pro-apoptotic molecules are
involved in the early phase of mTBI (Zetterberg et al., 2013).
Interestingly, it has also been reported that peripheral immune
cells, such as mast cells and T-cells are implicated in this
process (Kelso and Gendelman, 2014; Corrigan et al., 2016).
Despite recent advances in the knowledge of the mechanisms
involved in mTBI, no treatments, except for palliative care,
are currently available (Loane and Faden, 2010). It is currently
believed that the secondary neuropsychiatric changes that occur
as a consequence of TBI are linked to plastic rearrangements
in several brain areas including the hippocampal and medial
prefrontal cortex (mPFC) circuitry (Schwarzbold et al., 2008).
The mPFC is also thought to play a key role in chronic pain-
related negative affective states (i.e., anxiety, depression, and
cognitive impairments), which are often present as comorbidities
accompanying damages to the central or peripheral nervous
system (CNS or PNS, respectively), such as neuropathy or
trauma. Among the neurotransmitters and neuromodulators
involved in the central sequelae of TBI, endocannabinoids
(eCBs) have previously been shown to be involved in the
pathogenesis of CNS-related disorders, and more recently, in
their underlying mechanisms as well (Shohami et al., 2011;
Mann et al., 2016). In particular, a recent study indicates that
preventing the degradation of endogenous cannabinoid ligands
after mild TBI attenuates neuroinflammation and improves the
recovery of neurobehavioral function during the first 7 days post-
TBI induction (Mayeux et al., 2016). In addition to classical
eCBs, endocannabinoid-related N-acylethanolamines, such as
Palmitoylethanolamide (PEA) have been shown to participate
in TBI-mediated dysfunctions (Ahmad et al., 2012; Cuzzocrea
et al., 2012). PEA is an endogenous lipid compound belonging to
the fatty acid ethanolamide (FAE) family, which is derived from
the reaction between ethanolamine and palmitic acid. PEA is
highly expressed in the mammalian brain and exerts considerable
pharmacological effects when supplied exogenously (Lo Verme
et al., 2005a,b), as a drug, or when its endogenous levels are
enhanced through the inhibition of its catabolism (Solorzano
et al., 2009). In particular, PEA has been shown to be involved
in neuroprotective mechanisms that are activated under several
pathological states, including chronic pain (Luongo et al., 2013;
D’Agostino et al., 2015; Di Cesare Mannelli et al., 2015; Guida
et al., 2015) and other CNS-related disorders associated with
neuroinflammation (Skaper et al., 2013).
In the present study, we aimed to characterize the behavioral
and electrophysiological phenotype of 60-day mild-TBI mice
and to investigate the effect of chronic PEA administration
on the associated sensorial and neuropsychiatric dysfunctions.
We evaluated (i) chronic pain symptoms (allodynia and
hyperalgesia) and affective-cognitive impairments including
anxiety/depression, aggressive, recklessness-like behaviors and
reduced sociability at 14 and 60 days post-trauma; (ii) the bio-
molecular and electrophysiological changes occurring in the
m-PFC; and (iii) the effects of repeated PEA administration on
behavioral and functional changes in TBI mice.
MATERIALS AND METHODS
Animals
Male C57BL/6 mice (Charles River, Italy) weighing 18–20 g
were housed three per cage under controlled illumination (12 h
light/dark cycle; light on 6:00 A.M.) and standard environmental
conditions (ambient temperature 20–22◦C, humidity 55–60%)
for at least 1 week before the commencement of experiments.
Mice chow and tap water were available ad libitum. The
experimental procedures were approved by the Animal Ethics
Committee of Università della Campania “L. Vanvitelli”, Naples.
Animal care was in compliance with Italian (D.L. 116/92) and
European Commission (O.J. of E.C. L358/1 18/12/86) regulations
on the protection of laboratory animals. All efforts were made
to reduce both animal numbers and suffering during the
experiments.
Mild mTBI
Experimental mTBI was performed using a weight-drop device
developed in our laboratory. Mice were anesthetized with
intraperitoneal injection of Avertin (250 mg/kg) before being
subjected to mTBI. After a midline longitudinal incision, the
skull was exposed to locate the area of impact and placed
under a metal tube device where the opening was positioned
directly over the animal’s head. The injury was induced by
dropping a cylindrical metal weight (50 g), through a vertical
metal guide tube from a height of 20 cm. The point of
impact was between the anterior coronal suture (bregma) and
posterior coronal suture (lambda). Immediately following injury,
the skin was closed with surgical wound clips and mice were
placed back in their cages to allow for recovery from the
anesthesia and mTBI. Sham mice were submitted to the same
procedure as described for mTBI, but without release of the
weight.
Drugs
Ultra micronized (0.8–6.0 µm) Palmitoylethanolamide
(µm-PEA) was kindly provided by EPITECH Group SpA,
Saccolongo (PD).
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Behavioral Testing
Behavioral tests were performed from day 14 to 60 from mTBI
induction. At the end of each set of experiments mice were
sacrificed for further evaluations. The behavioral tests were
scheduled in order to avoid carry-over effects from prior testing
experience. The application of different pain stimuli -mechanical
or thermal- was performed in separate groups of animals in order
to avoid interferences in the nociceptive response. Timeline of
mTBI induction and related behavioral characterization is given
in the Figure 1.
Mechanical Allodynia
Mechanical allodynia was evaluated at 7, 14, and 34 days after
mTBI or sham surgery by the Dynamic Plantar Aesthesiometer
(Ugo Basile, Varese, Italy). Mice were allowed to move freely
in 1 of the 2 compartments of the enclosure positioned on
the metal mesh surface. Mice were adapted to the testing
environment for 30 min before any measurement was taken.
After that, the mechanical stimulus was delivered to the plantar
surface of the hindpaw of the mouse from below the floor
of the test chamber by an automated testing device. A steel
rod (2 mm) was pushed with electronical ascending force
(0–30 g in 10 s). When the animal withdrawn its hindpaw,
the mechanical stimulus was automatically withdrawn and the
force recorded to the nearest 0.1 g. Nociceptive responses for
mechanical sensitivity were expressed as mechanical withdrawal
thresholds (MWT) in grams. Each mouse served as its own
control, the responses being measured both before and after
surgical procedures. MWT were quantified by an observer blind
to the treatment.
Thermal Hyperalgesia
Thermal hyperalgesia was evaluated at 7, 14, and 34 days after
mTBI or sham surgery by the Plantar Test Apparatus (Ugo
Basile, Varese, Italy). On the day of the experiment each mouse
was placed in a plastic cage (22 cm × 17 cm × 14 cm;
length × width × height) with a glass floor. After 30 min
habituation period, the plantar surface of the hind paw was
exposed to a beam of radiant heat through the glass floor. The
radiant heat source consists of an infrared bulb (Osram halogen-
bellaphot bulb; 8 V, 50 W). A photoelectric cell detected light
reflected from the paw and turned off the lamp when paw
movement interrupted the reflected light. Data were expressed
as thermal withdrawal latency (TWL) in seconds and TWL was
automatically displayed to the nearest 0.1 s; the cut-off time was
20 s in order to prevent tissue damage. Each mouse served as its
own control, the responses being measured both before and after
surgical procedures. TWL were quantified by an observer blind
to the treatment.
Light-Dark Box
At 14 days after mTBI or sham surgery, mice were tested
to measure reckless behavior using ligh/dark box test.
The light–dark box (600 mm × 300 mm × 300 mm;
length × width × height) apparatus consisted into two
equally sized compartments: the dark compartment (black
perspex) was covered, whereas the light compartment (white
perspex) was open and brightly lit from above (∼150 lux). Access
between compartments was allowed through a partition door
(70 mm × 70 mm). At the beginning of the session, mice were
placed in the light compartment and were free to explore for
10 min. The time spent in in each compartment, latency of first
entry into the dark compartment and number of entries into
each compartment were recorded.
Resident-Intruder Test
At 14 days after mTBI or sham surgery, mice were tested for
aggressive behavior using a resident intruder test. Mice were
individually housed for 1 week in Plexiglas cages to establish
a home territory and to increase the aggression of the resident
experimental mice. To begin, food containers were removed and
an intruder mouse of the same gender was placed in a resident
home cage and resident–intruder interactions were analyzed for
10 min. The aggressive behavior of resident socially isolated mice
FIGURE 1 | Timeline of the experimental procedure of mild Traumatic Brain Injury (mTBI) induction and related behavioral characterization in
presence of vehicle or Palmitoylethanolamide (PEA) treatment.
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was characterized by an initial pattern of exploratory activity
around the intruder, which was followed by rearing and tail rattle,
accompanied in few seconds by wrestling and/or a violent biting
attack. The number of these attacks and latency to the first attack
during 10 min observation period was recorded.
Three Chambers Sociability Test
At 60 days after mTBI or sham surgery, mice were tested for social
interaction using a three-chambered social interaction apparatus.
A plexi-glass three-chambered box was custom-built as follows:
doorways in the two dividing walls had sliding covers to control
access to the outer-side chambers. The test consisted of two
consecutive stages of 5 and 10 min each. During the 5-min first
stage of habituation the mouse was allowed to freely explore the
three chambers of the apparatus, detecting at this stage any innate
side preference. After that the mouse was gently encouraged into
the central chamber and confined there briefly by closing the
side chamber doors. During the following 10-min stage sessions,
a custom-made stainless-steel barred cup (6.5 cm × 15 cm)
was placed upside down in one of the side chambers. A never-
before-met intruder, previously habituated, was placed into an
upside down identical cup in the other chamber. The time
spent sniffing each upside-down cup, the time spent in each
chamber and the number of entries into each chamber were
recorded.
Forced Swimming Test (FST)
The forced swimming test (FST) and tail suspension test (TST)
are used to assess and quantify the extent to which a mouse model
displays a depression-like activity. TST and FST were evaluated at
60 after mTBI or sham surgery, respectively.
Forced Swimming Test
Mice were placed in a large cylinder (30 cm × 45 cm) filled with
water at a temperature of 27◦C, for a 6-min period. The duration
of immobility was monitored during the last 4 min of the 6-
min test. Immobility period was defined as the time spent by
the animal floating in the water without struggling and making
only movements necessary to keep its head above the water.
Immediately afterward, the trial mice were placed under a heating
lamp to dry.
Tail Suspension Test (TST)
Mice were individually suspended by the tail on a horizontal
bar (50 cm from floor) using adhesive tape placed approximately
4 cm from the tip of the tail. The duration of immobility, recorded
in seconds, was monitored during the last 4 min of the 6-min test
by a time recorder. Immobility time was defined as the absence of
escape-oriented behavior. Mice were considered to be immobile
when they did not show any body movement, hung passively and
completely motionless.
In vivo Electrophysiology
Single Extracellular Neurons Recordings
Mice for electrophysiological recordings were anesthetized with
pentobarbital (50 mg/kg, i.p.) and placed in a stereotaxic device
(David Kopf Instruments, Tujunga, CA, USA). Body temperature
was maintained at 37◦C with a temperature-controlled heating
pad. In all surgical preparations, the scalp was incised and holes
were drilled in the skull overlying the site of recording, mPFC
(AP: +1.54–1.78 mm from bregma, L: 0.3–0.5 from midline
and V: –1.5–3 mm below dura) (Figure 4A) and the site of
stimulation, BLA (AP: –0.5–2.06 mm from bregma, L: 2.8–3.0
from midline at anteroposterior angle of 30◦, and V: –4.2–5 below
dura) according to the coordinates from the atlas of Franklin
and Paxinos (1997) (Figure 4B). Anesthesia was maintained
with a constant continuous infusion of propofol (5–10 mg/kg/h,
i.v.). A bipolar concentric electrode (NEX-100; Rhodes Medical
Instruments Inc., Summerland, CA, USA) connected to A320
stimulator (World Precision Instruments England) was lowered
into the caudal region of the BLA. After lowering of the
stimulating electrode into the BLA, a glass-insulated tungsten
filament electrode (3–5 MX) (FHC Frederick Haer & Co.,
Bowdoinham, ME, USA) was stereotaxically lowered into the
prelimbic cortex (PLC) in mPFC. The recorded signals were
amplified and displayed on a digital storage oscilloscope to ensure
that the unit under study was unambiguously discriminated
throughout the experiment. Signals were processed by an
interface CED 1401 (Cambridge Electronic Design Ltd., UK)
and analyzed through Spike2 software (CED, version 4) to
create peristimulus rate histograms (PSTHs) online and to
store and analyze digital records of single-unit activity off-
line. Configuration, shape, and height of the recorded action
potentials were monitored and recorded continuously. This
study only included neurons with a regular spiking pattern
and a spontaneous firing rate between 0.1 and 3.82 Hz that
were classified as pyramidal neurons in rodents (Jung et al.,
1998; Tierney et al., 2004; Floresco and Tse, 2007). Once a
neuron was single out, the position of the microelectrode
was adjusted to maximize the spike amplitude relative to
background noise and electrical stimuli into the BLA were
delivered.
Characterization of BLA-Evoked Responses and
Stimulation Protocol
We observed that BLA stimulation could evoke two distinct
types of firing changes: inhibition or excitation in separate
populations of mPFC neurons (Ishikawa and Nakamura, 2003).
Neurons responsive to BLA stimulation were stimulated with
100–200 pulses to determine the cell type. Specifically, a cell was
considered to be excited by BLA stimulation if it displayed a fast-
onset increase of firing and hereafter referred as “BLA→PLC(+)”
neurons (Floresco and Tse, 2007). This group of neurons showed
a cluster of spikes typically showing a Poisson distribution
and displayed an increased probability of spike firing after
BLA stimulation (200 µA) (Figure 4C). From the PSTHs, we
measured the duration of excitation (in seconds) as the period
of the increased firing activity which exceeds the average baseline
value +2SDs, the frequency of the evoked excitatory responses
and the onset of excitation, which was considered as the time
from the application of the stimulus artifact to the first evoked
spike exceeding the average baseline value +2SDs. These criteria
were used as an index of changes in the excitatory influence that
BLA inputs exert over mPFC neuron.
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A second group of neurons displaying a complete cessation
of spontaneous firing after BLA stimulation they are classified
as “BLA→mPFC(–)” neurons (Floresco and Tse, 2007)
(Figure 4D). Once a neuron, that was inhibited by BLA
stimulation, was isolated and characterized, a single-pulse
stimulation was delivered at 0.5 Hz using an initial stimulation
current of 200 µA. We typically used 100–250 sweeps to
generated on-line PSTHs. We measure the duration of
inhibition (in seconds), the period when the spontaneous
firing was completely suppressed, and the onset of inhibition
(in milliseconds), the time interval between the stimulus
application and last spike before a complete cessation of
neuronal activity, after BLA stimulation as defined by Ishikawa
and Nakamura (2003). By using these parameters, we could
have a reliable index of changes in the inhibitory influences that
BLA inputs exert over the mPFC neuron firing (Ishikawa and
Nakamura, 2003; Laviolette and Grace, 2006; Floresco and Tse,
2007).
Mechanical stimuli were applied to the hind paw (contralateral
to the mPFC) by Von Frey filaments with bending force
of 97.8 mN (noxious stimulation) for 2 s (Simone et al.,
2008) The mechanical stimulus evoked inhibitory or excitatory
response in separate populations of mPFC neurons. The same
parameters of the inhibitory and excitatory responses were
measured and considered as an index of mPFC neuron firing
response to mechanical noxious stimuli (Giordano et al., 2012).
Neurons that displayed no change in firing in response to
electrical or mechanical stimulation, were not considered for
recording.
Moreover, the extracellular action potentials’ (EAP)
amplitude, indicating synaptic current was used for the
evaluation of the efficacy of synaptic transmission (Fagni et al.,
1987). Data analysis was performed with Spike2 software
version 7.0.
Biochemical Analysis
Protein Extraction and Western Blot Analysis
For protein extraction, the PL-IL cortex was minced into small
pieces with a blender, then suspended in lysis buffer [HEPES
25 mM; EDTA 5 mM; SDS 1%; Triton X-100 1%; PMSF
1 mM; MgCl2 5 mM; Protease Inhibitor Cocktail (Roche,
Mannheim, Germany); Phospahatase Inhibitor Cocktail (Roche,
Mannheim, Germany)] and cleared by centrifugation (10 min
at 10,000 × g at 4◦C). Protein concentration was determined
using the method described by Bradford (1976). Each sample
was loaded (30 µg), electrophoresed in a 8 or 15% SDS-
polyacrylamide gel and electroblotted onto a polyvinylidene
difluoride (PVDF) membrane (EMD Millipore Corp., Billerica,
MA, USA). The membrane was blocked in 5% milk, 1X Tris-
buffered saline and 0,05% Tween-20. Primary antibodies to
detect IL-1β (1:500, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), IL-10 (1:500, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) Cox-2 (1:500, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), I-NOS (1:1000, Abcam, Cambridge,
UK) were used according to the manufacturer’s instruction.
Immunoreactive signals were detected with a horseradish
peroxidase-conjugated secondary antibody and reacted with
an ECL system (Amersham Pharmacia, Uppsala, Sweden).
Protein levels were normalized with respect to the signal
obtained with anti-beta-actin monoclonal antibodies (Sigma
Chemical Co. 1:1000 dilution). The semi-quantitative analysis
of protein levels was carried out by the ChemiDoc-It 5000,
using VisionWorks Life Science Image Acquisition and Analysis
software (UVP, Upland, CA, USA). Bradford M.M. A rapid
and sensitive method for the quantization of microgram
quantities of protein utilizing the principle of protein-dye
binding.
Statistical Analysis
Data were represented as mean ± SEM. The behavioral data
(n = 8–9) were analyzed using One-way Anova, followed
by Tukey post hoc. Electrophysiological data (n = 3–4) were
analyzed using one-way ANOVA, followed by Holm–Sidack post
hoc comparisons or t-test. Biomolecular data (n = 3) were
analyzed by One-way Anova, followed by Student–Neuman–
Keuls test.
RESULTS
PEA Reduces mTBI-Induced Pain
Behaviors
A significant decrease of MWT and TWL was observed in
vehicle-treated mTBI mice at 7 and 14 days after trauma
induction (MWT: 3.7 g ± 0.7, F(2,21) = 14.26, P = 0.0001,
and 4 g ± 0.6, respectively; TWL: 4.1 s ± 0.6, F(2,21) = 11.69,
P = 0.0004, and 3.0 s ± 0.5, respectively) compared to the sham
group (MWT: 7.6 g ± 0.3; MWT and 6.9 g ± 0.3, respectively;
TWL: 7 s ± 0.4 and 6.6 s ± 0.6, respectively) (Figures 2A,B).
No difference in pain threshold was observed between right and
left paw (data not shown). Moreover, a complete physiological
re-establishment of normal pain response was observed 34 days
after trauma induction (MWT: 6.9 g ± 0.4, F(2,21) = 1.112,
P = 0.3476; TWL:7.0 s ± 0.2, F(2,21) = 0.05148, P = 0.9499)
compared to the sham mice (MWT: 6.0 g± 0.3; TWL: 6.8 s± 1.1)
(Figure 2A,B). PEA repeated treatment (10 mg/kg, i.p., 14 days)
significantly reduced both the mechanical allodynia and thermal
hyperalgesia in mTBI mice at 14 days (MWT: 7.0 g ± 0.9,
F(2,21) = 7.014, P = 0.0046; TWL: 7.1 s ± 0.5, F(2,21) = 16.62,
P < 0.0001) as compared with vehicle (MWT: 4.0 g ± 0.6; TWL:
3.0 s± 0.5) (Figures 2A,B). No difference was observed between
right and left paw with PEA treatment (data not shown). The
vehicle or PEA administration in sham mice did not change the




Compared to the controls (214.2 s ± 19.5 and 20.44 ± 2.6),
mTBI mice did not show any significant change in the time
spent in the illuminated compartment of the light/dark box
(315.8 s ± 29.6, F(2,12) = 2, P = 0.71), as well as, in the
number of transitions in the two compartments(22.22 s ± 3.1;
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FIGURE 2 | Effects of repeated administration (14 days) of vehicle (Pluronic acid 5%) or PEA (10 mg/kg, i.p.) on behavioral evaluations in sham and
mTBI mice. (A) Shows mechanical withdrawal thresholds (MWT) measured through dynamic plantar aesthesiometer, (B) shows the thermal withdrawal latency
(TWL) in the plantar test, (C–E) show the latency to enter in the dark box, the time spent in light box and the number of transition in the light/dark box test,
respectively. (F,G) Show the latency to the first attack and the number of attack in the resident intruder test, respectively. Data are represented as mean ± SEM of
eight mice per group. ◦ and ∗ indicate significant differences compared to sham/vehicle or TBI/vehicle, respectively. P < 0.05 was considered statistically significant.
One-way ANOVA, followed by Tukey post hoc.
F(2,24) = 0.85; P = 0.53) at 14 days post trauma (Figures 2C,D).
However, mTBI condition caused a significantly increase in the
latency to enter in the dark box (256.2 s ± 13.2), that we
identify as recklessness-like behaviors (Figure 2E), as compared
to the control animals (101.6 s ± 6.7). The treatment with
PEA (10 mg/kg, i.p., 14 days) significantly decreased this effect
(52.5 s ± 9, F(2,24) = 112,9 P < 0.01) as compared with vehicle
(256.2 s ± 13.2), while did not affect the total time spent in
the light compartment and the number of transitions mediated
by mTBI (Figures 2C–E). Sham mice treated whit vehicle or
PEA did not show any change in time spent in the illuminated
compartment of the light/dark box, in the number of transition
in the two compartments or in the latency to enter the dark
compartment compared to naive or sham/vehicle mice (data not
shown).
PEA Reduces mTBI-Induced Aggressive
Behavior
Vehicle-mTBI mice showed a shorter latency to the first attack
(215.9 s ± 22.6) compared to sham animals (542.1 s ± 19.7)
14 days post trauma (Figure 2F). Additionally, compared to the
controls (1.2 ± 0.4), the number of attacks was dramatically
increased (9.7 ± 1.2) (Figure 2G). PEA administration
(10 mg/kg, i.p., 14 days) increased the latency to the first attack
(571.7 s ± 16.2; F(2,24) = 100.5; P < 0.001) and reduced the
number of attacks (0.7± 1.4, F(2,24) = 49.25; P < 0.001) of mTBI
mice, as compared with vehicle (215.9 s ± 22.6 and 9.7 ± 1.2,
respectively) (Figures 2F,G). Sham mice treated whit vehicle or
PEA did not show any change in the latency to the first attack or
number of attacks compared to naive or sham/vehicle mice (data
not shown).
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FIGURE 3 | Effects of repeated administration (14 days) of vehicle (Pluronic acid 5%) or PEA (10 mg/kg, i.p.) on behavioral evaluations in sham and
mTBI mice. (A,B) Show the duration of immobility in the tail suspension test and in the forced swimming test, respectively. (C) Shows the duration of the time spent
with an object or mouse in the three chambers sociability apparatus. Data are expressed in seconds and represented as mean ± SEM of 8–9 mice per group. ◦ and
∗ indicate significant differences compared to sham/vehicle or TBI/vehicle, respectively. P < 0.05 was considered statistically significant. One-way ANOVA, followed
by Tukey post hoc.
PEA Reduces the mTBI-Induced
Depressive-Like Behavior
mTBI mice showed an increased immobility time, measured as
the lack of escape-oriented activity (s) (91.7 s ± 1.3) compared
to the sham mice (20.2 s ± 1.0) in TST 60 days post trauma
(Figure 3A). Similarly, we found an enhanced duration of
immobility, measured as the time spent by the animal floating in
the water, in the FST (170.8 s ± 4.3) compared to the controls
(105.9 s ± 11.7) (Figure 3B). PEA treatment (10 mg/kg, i.p.,
14 days) significantly reduced the immobility in mTBI condition
in both paradigms (tail suspension: 44.5 s ± 1.8, F(2,21) = 636.4,
P < 0.0001; forced swimming: 107.1 s ± 5.4, F(2,21) = 22.35;
P < 0.001) compared to the vehicle (tail suspension: 91.7± 1.3 s;
forced swimming: 170.8 s ± 4.3) (Figures 3A,B). Sham mice
treated whit vehicle or PEA did not show any change in the
duration of immobility compared to naive or sham/vehicle mice
(data not shown).
PEA Reduces the mTBI-Induced
Impaired Social Behavior
Analysis of the social preference revealed an impairment of
social interaction which occurred 60 days post trauma. Indeed,
mTBI mice showed reduced sociability level, spending a lower
time in interacting with the objector mouse during the recorded
time (15.5 s ± 3.4), compared to sham animals (49.9 s ± 1.3)
(Figure 3C). No difference in the time spent in each chamber
or in the number of transitions between the chambers was
observed in mTBI mice treated with vehicle compared to the
sham mice treated with vehicle (not shown). The treatment with
PEA (10 mg/kg, i.p., 14 days) significantly improved the social
behavior in mTBI mice (67.2 s ± 7.1; F(2,21) = 41.81, P < 0.001)
compared to the with vehicle (15.5 s ± 3.4). Sham mice treated
whit vehicle or PEA did not show any change in sociability, the
time spent in the two chambers or in the number of transitions
between the chambers compared to naive or sham/vehicle mice
(data not shown).
Characterization of Electrical and
Mechanical Stimulation-Evoked
Responses of mPFC(+) Neurons in
SHAM and TBI Mice 14 and 60 Days after
Trauma
Single-unit extracellular recordings in anesthetized mice were
performed from individual neurons in the mPFC (Figure 4A).
The slow spontaneous firing rate of about 0.3–3.82± 0.4 spikes/s
from recorded neurons was consistent with presumed pyramidal
cells (Pérez-Jaranay and Vives, 1991; Floresco and Tse, 2007),
rather than fast-spiking interneurons, the latter having a higher
baseline firing rate (>10 Hz) and narrower spike waveform
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FIGURE 4 | Schematic illustration of the mPFC recording sites which are indicated by filled circles. Number values in mm indicate distance from bregma
(A). Representative schematic illustration showing the location of the recording electrode in cortex and of the stimulation electrode in the BLA. Number values refer
to stimulation parameters (B). BLA electrical stimulation evokes excitatory [BLA→ mPFC(+)] or inhibitory [BLA→ PLC(–)] responses in different mPFC neuron
populations. (C,D,F,G,I,J) Show peristimulus time histograms (PSTHs) of SHAM (C,D), TBI 14 days (F,G) and TBI 60 days mice (I,J) receiving subcutaneous vehicle
injection. PSTHs show responses of a single neuron to a pulse (200 µA intensity, black arrows) delivered at in the BLA at 0.5-Hz stimulation (vertical bar).
Representative average waveforms of SHAM (E), TBI 14 days (H), and TBI 60 days mice (K). Horizontal bar = 1 ms; vertical bar = 200 mV.
(<300 µs) (Constantinidis and Goldman-Rakic, 2002; Laviolette
and Grace, 2006). Firing rates were measured as the average rate
in spikes/s.
We investigated the mPFC neurons with ongoing activity that
responded with excitation [BLA→PLC(+)] and with inhibition
[BLA→mPFC(–)] to electrical and mechanical stimulation
(Gabbott et al., 2006; Figure 4). We first isolated mPFC neurons
and thereafter stimulated the BLA at 0.5 Hz using a stimulation
current of 200 µA (Figure 4B). Electrical stimulation outside
of the BLA did not induce any significant change in mPFC
pyramidal neuron activity. The neurons were first identified
by electrical stimulation, and subsequently stimulated with
mechanical noxius stimuli on the hind paw using von Frey
filaments (with bending force of 97.8 mN for 2 s; Simone et al.,
2008) for all the duration of the experiment (each single neuron
was recorded for at least 20 min) (Luongo et al., 2012).
BLA→PLC(+) neurons had a spontaneous firing rate of
0.30 ± 0.031 spikes/s in SHAM/veh group (Figure 4C). The
frequency, the duration and the onset of excitation were
3.18 ± 0.48 spikes/s, 3.56 ± 0.23 s and 960.1 ± 122 ms,
respectively, in SHAM/veh group (Figures 5E–G) (n = 9
neurons recorded from 3 to 4 mice per group). TBI mice
14 days after induction of trauma (TBI 14 dd/veh) showed
an increase in the spontaneous firing rate (1.020 ± 0.10
spikes/s; F(3,8) = 31.24, p < 0.001) (n = 9 neurons recorded
from 3 to 4 mice per group) (Figure 5B). Moreover, an
increase in the frequency of stimulation-evoked excitation of
BLA→mPFC (+) neurons (5.73 ± 0.33 spikes/s; F(3,8) = 10.92,
p < 0.01) and in the duration of excitation (5.36 ± 0.12 s;
F(3,8) = 5.34, p< 0.05) was observed, while the onset was reduced
(524.7 ± 32.38 ms; F(3,8) = 10.66, p < 0.05) (Figures 5E–G).
TBI mice 60 days after induction of trauma (TBI 60 dd/veh)
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FIGURE 5 | The figure shows different parameters of mechanical stimulus-evoked excitation in SHAM and TBI mice 14 and 60 days after trauma,
treated with vehicle or PEA (10 mg/kg, i.p.) for 14 days. (A) Shows schematic illustration of mechanical stimulation applied to the hind paw (contralateral to the
mPFC) which evokes excitatory responses in the prelimbic cortex (PLC). (B,C,I,J) Show representative PSTHs of a BLA→mPFC (+) neuron of SHAM and TBI 14
and 60 dd mice treated for 14 days with vehicle or PEA. Vertical bars indicate the mechanical stimuli which evoke excitation (hind paw stimulation by von Frey
filaments with bending force of 97.8 mN, gray arrows). (D–G,K–O) Show the mean ± standard error (SEM) of the mean of spontaneous activity, of the frequency, of
the duration and of the onset of excitation in different groups of mice. (H,O) Show relative EAP slopes recorded in different groups of mice. ◦ Indicates statistically
significant difference versus SHAM/veh mice; ∗ indicates statistically significant difference versus TBI 14 dd/veh or TBI 60dd/mice. p < 0.05 has been considered as
value of significance. The double symbol indicates p < 0.01 and the triple symbol indicates p < 0.001. One-way ANOVA, followed by Holm–Sidack post hoc
comparisons or t-test.
showed a further impairment in electrophysiological parameters.
In particular, the spontaneous activity was significantly reduced
(0.10 ± 0.01 spikes/s) with respect to both TBI 14 dd/veh
group (p < 0.001) and to SHAM/veh group (F(3,8) = 16.77,
p < 0.001) (n = 9 neurons recorded from 3 to 4 mice per
group) (Figure 5K). With a similar fashion, the frequency
and the duration of excitation were decreased (1.55 ± 0.12
spikes/s and 2.03 ± 0.16 s, respectively) with respect to both
TBI 14 dd/veh group (p < 0.01) and to SHAM/veh group
(F(3,8) = 7.05, p < 0.05 and F(3,8) = 6.86, p < 0.05, respectively)
(Figures 5M,N). Whereas, the onset was significantly increased
(1824 ± 34.19 ms) as compared to both TBI 14 dd/veh group
(p < 0.05) and to SHAM/veh group (F(3,8) = 25.14, p < 0.01).
We quantified the slope of the initial negative-going EAP
response, which reflects the early activation of the mPFC. In
SHAM mice the slope of the EAP was –3.33 ± 0.33 mV/ms
and it significantly increased 14 days (–7.66 ± 0.33 mV/ms,
F(3,8) = 18.47, p < 0.001) and 60 days (–7,66 ± 0.66 mV/ms,
F(3,8) = 20.85, p < 0.001) after trauma (Figures 5H,O,
respectively).
Characterization of Electrical and
Mechanical Stimulation-Evoked
Responses of mPFC(–) Neurons in SHAM
and TBI Mice 14 and 60 Days after
Trauma
BLA→PLC(–) neurons had a spontaneous firing rate of
3.82 ± 0.12 spikes/s in SHAM/veh group (Figure 6D). The
duration and the onset of inhibition were 3.54 ± 0.29 s and
Frontiers in Pharmacology | www.frontiersin.org 9 March 2017 | Volume 8 | Article 95
fphar-08-00095 March 2, 2017 Time: 17:9 # 10
Guida et al. Palmitoylethanolamide in Mild Traumatic Brain Injury
FIGURE 6 | The figure shows different parameters of mechanical stimulus-evoked excitation in SHAM and TBI mice 14 and 60 days after trauma,
treated for 14 days with vehicle or PEA (10 mg/kg, i.p.). (A) shows schematic illustration of mechanical stimulation applied to the hind paw (contralateral to the
mPFC) who evokes inhibiting responses in the prelimbic cortex. (B,C,H,I) Show representative PSTHs of a BLA→mPFC (–) neuron of SHAM and TBI mice 14 and
60 days after trauma, treated for 14 days with vehicle or PEA. Vertical bars indicate the mechanical stimuli which evoke inhibition (hind paw stimulation by von Frey
filaments with bending force of 97.8 mN, gray arrows). (D–F,J–L) Show the mean ± standard error of the spontaneous activity, of duration and of onset of inhibition
in different groups of mice. (G,M) show relative EAP slopes recorded in different group of mice. ◦ indicates statistically significant difference versus SHAM/veh mice;
∗ indicates statistically significant difference versus TBI 14 dd/veh or TBI 60 dd/veh mice. p < 0.05 has been considered as value of significance. The double symbol
indicates p < 0.01 and the triple symbol indicates p < 0.001. One-way ANOVA, followed by Holm–Sidack post hoc comparisons or t-test.
1844 ± 247.6 ms, respectively (Figures 6E,F) (n = 9 neurons
recorded from 3 to 4 mice per group). TBI mice 14 days
after induction of trauma (TBI 14 dd/veh) showed an increase
in the duration of inhibition (8.97 ± 0.38 s; F(3,8) = 97.95,
p < 0.05) and a decrease in the onset (153.6 ± 11.78 ms;
F(3,8) = 19.04, p < 0.001) and in the frequency of ongoing
activity (0.71 ± 0.23 spikes/s; F(3,8) = 36.81, p < 0.0001)
of BLA→mPFC (–) neurons (n = 9 neurons recorded from
three mice per group) (Figures 6D–F). TBI mice, 60 days
after induction of trauma (TBI 60 dd/veh), showed severe
changes in electrophysiological parameters. In fact, the duration
(1824 ± 34.19 ms; F(3,8) = 48.83, p < 0.001) and the onset
of inhibition (25.50 ± 4.50 ms; F(3,8) = 5.34, p < 0.05) were
significantly increased while the frequency of ongoing activity
(0.23 ± 0.04 spikes/s; F(3,8) = 100.9, p < 0.01) was significantly
reduced as compared to SHAM/veh group (Figures 6J–L). The
TBI also induced a significant increase of EAP slope values at
14 days (–7.66 ± 0.33 mV/ms; F(3,8) = 17.58, p < 0.01) and
60 days (7,66± 0.66 mV/ms; F(3,8) = 9.7, p< 0.05), as compared
to the controls (4.33± 0.33 mV/ms) (Figures 6G,M).
Effect of PEA on BLA→PLC(+) Neurons
in TBI Mice 14 and 60 Days after Trauma
Repeated treatments with PEA (10 mg/kg) did not affect neither
spontaneous nor stimulus-evoked activity of BLA→mPFC(+)
neurons in SHAM mice (n = 9 neurons recorded from 3 to
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4 mice) as compared to vehicle-treated group (Figure 5). On
the contrary, TBI 14 dd mice treated with PEA (10 mg/kg i.p.)
showed a normalization in the frequency of ongoing activity
(0.17 ± 0.09 spikes/s, F(3,8) = 31.24, p < 0.001), in the duration
of evoked frequency (2.84 ± 0.5 s, F(3,8) = 5.34, p < 0.001), in
the frequency of excitation (3.58± 042 spikes/sec; F(3,8) = 10.92,
p < 0.05) and in the EAP slope (–5.33 ± 0.33 mV/ms,
F(3,8) = 29.58, p < 0.01) (Figures 5D–H). At the same time, a
significant increase in the onset of excitation (1366 ± 166.5 ms,
F(3,8) = 10.66, p < 0.001) was observed, as compared to TBI 14
dd/vehicle (Figure 5E). The treatment with PEA (10 mg/kg) did
not affect the electrophysiological parameters in TBI 60 days after
trauma (Figure 5).
Effect of PEA on BLA→PLC(–) Neurons
in TBI Mice 14 and 60 Days after Trauma
Repeated treatments with PEA (10 mg/kg) did not affect neither
spontaneous nor stimulus-evoked activity in BLA→mPFC(–)
neurons in SHAM mice (n = 9 neurons recorded from 3 to
4 mice). Treatment with PEA (10 mg/kg i.p.) normalized the
duration of inhibition (3.78 ± 0.24 s, F(3,8) = 67.95, p < 0.05)
and the EAP slope (–4.66± 0.33 mV/ms, F(3,8) = 17.58, p< 0.05)
(Figures 6E,G).
Instead, the firing rate (1.44 ± 0.29 spikes/sec, F(3,8) = 36.81,
p < 0.05) and the onset of inhibition (1999 ± 187.5 ms,
F(3,8) = 19.04, p< 0.001) resulted increased in TBI 14 dd mice as
compared to TBI 14 dd/vehicle (Figures 6D,F). The treatment
with PEA (10 mg/kg) did not affect the electrophysiological
parameters previously analyzed in TBI 60 days after trauma
(Figure 6).
PEA Normalizes the mTBI-Induced
Increased IL-1β Levels
Western blot analysis revealed a significant increase of the pro-
inflammatory cytokine IL-1β protein levels in the PL-IL of
TBI/vehicle-treated mice as compared to SHAM/vehicle animals
14 days after injury. Instead protein levels of IL-10, iNOS,
and COX-2 did not change in TBI mice. Treatment with PEA
(10 mg/kg/day, i.p.) decreased the protein levels of IL-1β in
TBI mice (F(2,6) = 24.75, p < 0.05), without affecting IL-10
(F(2,6) = 2.10), I-NOS (F(2,6) = 0.71), and COX-2 (F(2,6) = 0.56)
TABLE 1 | The protein levels (mean ± SEM) of the proteins under analysis
measured by western blot are reported.
Protein (CTX) SHAM/vehicle TBI/vehicle TBI/PEA ultra
IL-ip/p-actin 100.0 ± 10.0 150.0 ± 4.0◦ 78.0 ± 7.0∗
IL-10/p-actin 100.0 ± 22.5 84.0 ± 7.5 55.0 ± 13.4
COX-2/p-actin 100.0 ± 13.3 100.0 ± 9.8 114.0 ± 8.8
I-NOS/p-actin 100.0 ± 28.6 112.0 ± 29 67.0 ± 25
The analysis of protein levels was carried out by the ChemiDoc-It 5000, using
VisionWorks Life Science Image Acquisition and Analysis software (UVP, Upland,
CA, USA). The measured protein levels were normalized with respect to β-actin
(housekeeping gene) and protein expression values were expressed as arbitrary
units ± SEM. ◦ vs Sham/vehicle and ∗p < 0.05 vs. TBI/vehicle, as analyzed by
One-way ANOVA, followed by Student–Neuman–Keuls test.
protein levels (see Table 1 and Supplementary Figure S1). For
all proteins examined, naïve and SHAM animals showed no
differences in the expression levels (data not shown).
DISCUSSION
Despite early brain damage, mild TBI is commonly associated
with a late manifestation of psychologically debilitating
symptoms and cognitive impairments, for which adequate
treatment is currently unavailable. In the present study, we
have characterized the behavioral phenotype associated with
the late phase of TBI (up to 60 days post-trauma), as well as
have investigated possible supraspinal changes, i.e., cytokine
profile and electrophysiological neuronal activity. Our results
show that mTBI induces a characteristic dual behavioral
phenotype (aggressive/depressive), possibly by regulating
biochemical and electrophysiological processes in the mPFC.
As has been previously reported in humans (DSM V), mTBI
mice developed aggressive and recklessness-like behaviors in
an early phase; 2 weeks after trauma induction. At this stage,
they also displayed abnormal pain perception, described as
mechanical allodynia. Chronic pain is a common comorbidity
of TBI (Ofek and Defrin, 2007; Nampiaparampil, 2008), and
nociceptive sensitization of areas that are far from the injury site
has previously been observed (Feliciano et al., 2014). Though the
mechanism by which TBI may affect the peripheral nociceptive
threshold is unknown, recent data suggest that brain damage
may induce an increase in proinflammatory molecules that
then leak to the periphery, contributing to the development
of pain (Feliciano et al., 2014; Rowe et al., 2016). In the
current study, the recklessness-like behavior and abnormal pain
perception were self-limited after 2 and 3 weeks, respectively.
Interestingly, aggressiveness, which was still present 60 days
after trauma, was accompanied by depressive-like behavior,
determined by absence of escape-oriented activity and increased
immobility. Furthermore, TBI animals showed social interaction
impairments, which are also frequently observed in patients and
are thought to reflect underlying cognitive impairments caused
by the trauma (Byom and Turkstra, 2016).
Our data also revealed that mTBI deeply affects cortical
neuronal activity. In fact, a similar behavioral profile was
correlated with the biphasic firing activity of the pyramidal
neurons in the mPFC, which is considered a key substrate
regulating negative affective states, including anxiety and
depression (Vialou et al., 2014; Apps and Strata, 2015).
Specifically, (BLA)-mPFC(–) inhibitory and BLA-mPFC(+)
excitatory neurons, which concurrently respond to hind-paw
pressoceptive stimuli, showed phenotypic changes following
brain injury, suggesting that the mPFC may undergo profound
reorganization in response to the trauma. Additionally, 14 days
after trauma, cells that had an excitatory response to stimulation,
showed an increase in both their spontaneous and evoked firing
activity, whereas those of inhibitory cells appeared reduced.
However, at 60 days of mTBI, we observed a pathological cortical
hypofunctionality, characterized by an overall depressed pattern
of neuronal activity. These findings suggest that brain trauma
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may implicate an alteration of the balance between excitatory
and inhibitory transmission in the BLA-mPFC circuit, and
consequently impair the broad complexity of tasks attributed
to PFC activity. Previous studies have shown that an increased
inflammatory response associated with microglial activation,
peripheral immune cell infiltration, and cytokine release is
elicited within a few days following a traumatic episode (Hall
et al., 2010; Woodcock and Morganti-Kossmann, 2013; Gao et al.,
2016). Interestingly, we found increased levels of interleukin 1
beta (IL-1β) at cortical levels, 14 days post-trauma, whereas no
differences in the expression levels of classical pro-inflammatory
mediators, including iNOS and COX2, were observed. The
augmented levels of supraspinal IL-1β and the subsequent IL-1
receptor activation is a central mechanism in several pathological
conditions (Giordano et al., 2012; Lampa et al., 2012). In
agreement with its pro-inflammatory profile, previous studies
also proved that IL-1β has a direct influence on cortical synaptic
transmission and plasticity, which may increase the risk of
cognitive decline and dysfunction (Tong et al., 2012; del Rey
et al., 2013). Moreover, direct IL-1β-mediated plasticity has been
shown in patients with multiple sclerosis (Mori et al., 2014;
Nisticò et al., 2014). Thus, based on the present results, we can
hypothesize that IL-1β might also be involved in the remodeling
and/or increased activity of the mPFC pyramidal neurons as has
previously been shown for chronic pain conditions (Giordano
et al., 2012).
In this study, we also confirm the beneficial effects of PEA, a
commercially available medical supplement, on the psychiatric
outcomes of TBI. The anti-inflammatory/neuroprotective
effects of PEA have been clearly shown in several pathological
conditions, including TBI (Ahmad et al., 2012; Cordaro et al.,
2016). However, here we show the effectiveness of PEA in
reducing mTBI-induced late-onset (60 days post-trauma)
psychiatric dysfunctions as well as its effect on the modulation
of neuronal activity. Specifically, PEA reverted recklessness-
like behaviors and abnormal pain perception (observed at 14
days) as well as normalizing the emotional/affective impairments
(depression and impaired sociability), which developed 60 days
post-trauma. Importantly and in accordance with the behavioral
data, electrophysiological experiments revealed that PEA
normalized the firing activity of the pyramidal neurons in the
mPFC of 14-day-TBI mice. This confirms the role of this lipid
signaling molecule in processes related to pain as well as its
involvement in neurological and emotional processes linked to
CNS damage (Martinez-Vargas et al., 2013). Surprisingly, while
PEA reverted the depression and reduced sociability seen in 60-
day TBI-mice, it was not able to modify the observed mPFC
electrophysiological changes. This suggests the involvement of
other brain areas, including the hippocampus and/or other
complex circuitries in the altered neuropsychiatric behavioral
profile of mTBI mice. Nevertheless, we cannot exclude the
possibility that the rearrangement of cortical activity, detected 60
days after mTBI induction, may have been responsible for other
behavioral changes, including cognition, memory and reward,
which were not analyzed in the present study.
CONCLUSION
Our results demonstrate that TBI causes late sensorial
affective/cognitive impairments linked to altered levels of cortical
IL-1β, as well as phenotypic changes in the pyramidal neurons
of the mPFC. These might represent the effect of a chronic
maladaptive process that arises in response to injury-induced
damage. Moreover, we showed that chronic PEA treatment
partially reduces behavioral dysfunctions by restoring cortical
biochemical and electrophysiological processes. Taken together,
our results suggest that treatment with PEA could represent
a novel approach for the management of neuropsychiatric
disorders associated with TBI.
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